Can a Cure Be Achieved with Taxane-Based Chemotherapy plus Surgery in Patients with Primary Mediastinal Non-Seminomatous Germ Cell Tumors and Progression or Relapse Despite First-Line Chemotherapy?

被引：0
|
作者：
Miskovska, Vera [1 ,2 ]
Levy, Antonin [1 ]
Massard, Christophe C. [1 ]
Gross-Goupil, Marine [1 ]
Bossi, Alberto [1 ]
Fizazi, Karim [1 ]
机构：
[1] Inst Gustave Roussy, Dept Med, Villejuif, France
[2] St Elisabeth Canc Inst, Bratislava, Slovakia
来源：
ONKOLOGIE | 2010年 / 33卷 / 03期
关键词：
mediastinal non-seminomatous germ cell tumor; primary; Taxane; Relapse; CISPLATIN-BASED CHEMOTHERAPY; HIGH-DOSE CHEMOTHERAPY;
D O I：
10.1159/000277824
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Primary mediastinal non-seminomatous germ cell tumors (NSCGTs) have a poor prognosis in the International Germ Cell Cancer Collaborative Group (IGCCCG) classification. There is no clear standard of treatment at relapse. Between 1995 and 2005, 13 patients experienced progression or relapse, and 1 patient was cured with a taxane-based chemotherapy plus surgical resection at our institution.
引用
收藏
页码：119 / 120
页数：2
相关论文
共 38 条
  • [31] Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial
    Gridelli, Cesare
    Bennouna, Jaafar
    de Castro, Javier
    Dingemans, Anne-Marie C.
    Griesinger, Frank
    Grossi, Francesco
    Rossi, Antonio
    Thatcher, Nick
    Wong, Elaine K.
    Langer, Corey
    CLINICAL LUNG CANCER, 2011, 12 (06) : 407 - 411
  • [32] A phase 2 randomized open-label study of ramucirumab (RAM) plus first-line platinum-based chemotherapy in patients (pts) with recurrent or advanced non-small cell lung cancer (NSCLC): Final results from squamous pts
    Thomas, S.
    Doebele, R. C.
    Spigel, D.
    Tehfe, M.
    Reck, M.
    Verma, S.
    Zimmermann, A.
    Alexandris, E.
    Lee, P.
    Bonomi, P.
    ANNALS OF ONCOLOGY, 2017, 28
  • [33] Pretreatment Fibrinogen-Albumin Ratio (FAR) Associated with Treatment Response and Survival in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Anti-PD-1 Therapy Plus Platinum-Based Combination Chemotherapy
    Yuan, Chengliang
    Huang, Meifang
    Wang, Huilin
    Jiang, Wei
    Su, Cuiyun
    Zhou, Shaozhang
    CANCER MANAGEMENT AND RESEARCH, 2022, 14 : 377 - 386
  • [34] A randomized phase II multi-institutional trial of anlotinib plus docetaxel versus docetaxel in EGFR-wild-type non-small cell lung cancer (NSCLC) patients after progression on first-line platinum-base chemotherapy: ALTER-L018.
    Wu, Lin
    Wu, Zhijun
    Xiao, Zemin
    Weng, Jie
    Ma, Zhongsha
    Chen, Yanhua
    Xiao, Maoliang
    Cao, Yongqing
    Duan, Huaxin
    Cao, Peiguo
    Zhang, Hui
    Wang, Qianzhi
    Li, Jia
    Xu, Yan
    Pu, Xingxiang
    Li, Kang
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] First-line (1L) nivolumab (N) plus ipilimumab (I) with 2 cycles of platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): Results from an interim analysis of the German non-interventional study (NIS) FINN
    Kuon, J. B.
    Von der Heyde, E.
    Sadjadian, P.
    Bischoff, M.
    Hassler, A.
    Althoff, A.
    Wilop, S.
    Behringer, D. M.
    Blau, W.
    Huebner, G.
    Flieger, D.
    Ziske, C.
    Groschek, M.
    Laack, H-E.
    Mueller-Huesmann, H.
    Schumann, C.
    Waldenberger, D.
    Guetz, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S852 - S852
  • [36] Safety and Efficacy of Necitumumab (N) During Single-Agent Treatment to Progression Following Gemcitabine-Cisplatin (GC) Chemotherapy Plus Necitumumab (IMC-11F8/LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (sq-NSCLC) (SQUIRE)
    Socinski, M. A.
    Thatcher, N.
    Luft, A. V.
    Szczesna, A.
    Ciuleanu, T.
    Szafranski, W.
    Ramlau, R.
    Balint, B.
    Kazarnowicz, A.
    Molinier, O.
    Depenbrock, H.
    Nanda, S.
    Obasaju, C.
    Paz-Ares, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S31 - S32
  • [37] A protocol pre-specified interim overall survival (OS) analysis of GEMSTONE-302: A phase 3 study of sugemalimab (suge) versus placebo plus platinum-based chemotherapy (chemo) as first-line (1L) treatment for patients (pts) with metastatic non-small cell lung cancer (NSCLC).
    Zhou, Caicun
    Wang, Ziping
    Sun, Meili
    Cao, Lejie
    Ma, Zhiyong
    Wu, Rong
    Yu, Yan
    Yao, Wenxiu
    Sun, Si
    Chen, Jianhua
    Zhuang, Wu
    Cui, Jiuwei
    Chen, Xueqin
    Lu, You
    Hu, Chunhong
    Wang, Jingru
    Chen, Rumei
    Qin, Mengmeng
    Wang, Hao
    Yang, Jason
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] AvaALL: Open-label randomized phase IIIb trial evaluating the efficacy and safety of standard of care with or without continuous bevacizumab (BV) treatment beyond disease progression in patients (pts) with advanced nonsquamous non-small cell lung cancer (NSCLC) after first-line (1L) treatment with BV plus platinum-doublet chemotherapy (CT).
    Gridelli, Cesare
    Bennouna, Jaafar
    De Castro, Javier
    Dingemans, Anne-Marie C.
    Griesinger, Frank
    Grossi, Francesco
    Thatcher, Nick
    Ohe, Yuichiro
    Diego Perez-Moreno, Pablo
    Langer, Corey J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
1234